Moore Capital Management LP Makes New $2.67 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Moore Capital Management LP acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,487 shares of the medical research company's stock, valued at approximately $2,674,000.

Other hedge funds also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $37,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $48,000. Finally, Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CRL. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research report on Wednesday. Morgan Stanley dropped their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Finally, The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $172.31.

Charles River Laboratories International Stock Performance

CRL stock traded up $2.11 during midday trading on Friday, reaching $141.00. The company had a trading volume of 1,473,414 shares, compared to its average volume of 982,521. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $135.94 and a 200 day moving average price of $165.27. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The firm has a market capitalization of $6.93 billion, a PE ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm posted $2.27 earnings per share. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 5,040 shares of company stock worth $807,407 over the last ninety days. Company insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).